November 16, 2017 / 12:49 PM / a month ago

BRIEF-Alnylam initiates rolling submission of NDA to U.S. FDA for HATTR amyloidosis treatment

Nov 16 (Reuters) - Alnylam Pharmaceuticals Inc

* Alnylam initiates rolling submission of new drug application (NDA) to U.S. Food and drug administration (FDA) for patisiran for the treatment of hereditary ATTR (HATTR) amyloidosis

* Alnylam Pharmaceuticals - ‍has also requested priority review of application for patisiran, if granted, could result in a 6-month review process ​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below